Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
Top Page
Forte Biosciences
(NASDAQ:FBRX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$25.00
▼(-4.83% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by weak financial performance driven by no revenue, widening losses, and accelerating cash burn. Technicals are mixed with soft near-term trend indicators, while valuation provides limited support due to negative earnings and no dividend data.
Positive Factors
Low Leverage
A debt-free balance sheet reduces fixed financial obligations and interest burden, preserving flexibility for a pre-revenue biotech. This structural strength lengthens runway options, lowers bankruptcy risk, and makes equity/dilution the primary lever for funding clinical programs.
Negative Factors
No Revenue Base
Being pre-revenue is a structural constraint: the company must fund R&D and operations exclusively via external financing until commercialization. This elevates execution and financing risk over the next several quarters and means commercial success is required to materially alter the fundamental risk profile.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A debt-free balance sheet reduces fixed financial obligations and interest burden, preserving flexibility for a pre-revenue biotech. This structural strength lengthens runway options, lowers bankruptcy risk, and makes equity/dilution the primary lever for funding clinical programs.
Read all positive factors
Forte Biosciences (FBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$364.78M
Dividend YieldN/A
Average Volume (3M)97.46K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS Growth77.08%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.39
Shares Outstanding13,885,668
10 Day Avg. Volume83,173
30 Day Avg. Volume97,456
Financial Highlights & Ratios
PEG Ratio0.94
Price to Book (P/B)65.81
Price to Sales (P/S)0.00
P/FCF Ratio-78.70
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.12
Forecast
1Y Price Target
$75.00Price Target Upside185.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.31
Revenue Forecast (FY)N/A
Forte Biosciences Business Overview & Revenue Model
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in ...
How the Company Makes Money
null...
Forte Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -39.00K | -9.00K | 0.00 | -36.00K |
| EBITDA | -70.59M | -35.44M | -32.48M | -13.86M | -21.45M |
| Net Income | -69.38M | -35.48M | -31.48M | -13.86M | -21.71M |
Balance Sheet | |||||
| Total Assets | 82.78M | 61.56M | 38.98M | 42.00M | 43.31M |
| Cash, Cash Equivalents and Short-Term Investments | 76.96M | 58.37M | 37.13M | 41.10M | 42.04M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 21.79M | 9.08M | 3.67M | 3.18M | 1.76M |
| Stockholders Equity | 60.99M | 52.48M | 35.31M | 38.82M | 41.55M |
Cash Flow | |||||
| Free Cash Flow | -51.00M | -30.78M | -28.79M | -8.19M | -16.68M |
| Operating Cash Flow | -50.88M | -30.75M | -28.71M | -8.19M | -16.68M |
| Investing Cash Flow | 36.23M | -35.99M | 47.00K | 0.00 | 0.00 |
| Financing Cash Flow | 69.36M | 51.86M | 24.68M | 7.24M | -44.00K |
Forte Biosciences Technical Analysis
Positive
26.27
Price Trends
28.48
Negative
26.15
Positive
19.10
Positive
Market Momentum
-0.63
Negative
47.65
Neutral
48.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBRX, the sentiment is Positive. The current price of 26.27 is above the 20-day moving average (MA) of 25.99, below the 50-day MA of 28.48, and above the 200-day MA of 19.10, indicating a neutral trend. The MACD of -0.63 indicates Negative momentum. The RSI at 47.65 is Neutral, neither overbought nor oversold. The STOCH value of 48.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBRX.
Forte Biosciences Risk Analysis
Forte Biosciences disclosed 71 risk factors in its most recent earnings report. Forte Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Forte Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $181.29M | -21.41 | -13.46% | ― | 35.42% | ― | |
52 Neutral | $254.81M | -1.00 | 789.35% | ― | -72.54% | -19972.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $809.92M | ― | -63.06% | ― | ― | 59.04% | |
48 Neutral | $282.32M | -3.97 | -36.38% | ― | ― | 48.84% | |
47 Neutral | $130.56M | -1.23 | -271.32% | ― | -75.77% | -31.24% | |
45 Neutral | $364.78M | -40.48 | -110.72% | ― | ― | 77.08% |
* Healthcare Sector Average
FBRX
Forte Biosciences
26.27
20.57
360.88%
CHRS
Coherus Biosciences
1.70
0.91
114.11%
SLS
SELLAS Life Sciences Group
4.86
3.74
333.93%
PLX
Protalix
2.25
-0.09
-3.85%
TARA
Protara Therapeutics
5.22
1.22
30.50%
IPHA
Innate Pharma
1.45
-0.37
-20.11%
Forte Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Forte Biosciences Prices $150 Million Public Offering
Positive
Apr 9, 2026
On April 8, 2026, Forte Biosciences, Inc. priced a public offering of 5,709,936 shares of common stock at $26.27 per share, with gross proceeds expected to be about $150 million and closing anticipated around April 10, 2026, subject to customary c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.